Biotech · Public company · Waltham, MA, US

Zenas BioPharma, Inc.

Ticker ZBIO · SEC CIK 0001953926

Track this companyFree. Adds Zenas BioPharma, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials55 recruiting or active

Pipeline programs5From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline5

ObexelimabPhase 3 · IgG4 Related DiseaseClinicalTrials.gov · fetched Nov 12, 2026
OrelabrutinibPhase 3 · Multiple Sclerosis (MS) Primary ProgressiveClinicalTrials.gov · fetched Nov 12, 2026
OrelabrutinibPhase 3 · Secondary Progressive Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
ObexelimabPhase 2 · Relapsing Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
ObexelimabPhase 2 · Systemic Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026

A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisPHASE3 · RECRUITING · started Mar 23, 2026ClinicalTrials.gov NCT07067463 · fetched Nov 12, 2026
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple SclerosisPHASE3 · RECRUITING · started Mar 23, 2026ClinicalTrials.gov NCT07299019 · fetched Nov 12, 2026
A Study of Obexelimab in Patients With Systemic Lupus ErythematosusPHASE2 · ACTIVE_NOT_RECRUITING · started Sep 17, 2024ClinicalTrials.gov NCT06559163 · fetched Nov 12, 2026
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)PHASE2 · ACTIVE_NOT_RECRUITING · started Aug 26, 2024ClinicalTrials.gov NCT06564311 · fetched Nov 12, 2026
A Phase 3 Study of Obexelimab in Patients With IgG4-Related DiseasePHASE3 · ACTIVE_NOT_RECRUITING · started Jan 9, 2023ClinicalTrials.gov NCT05662241 · fetched Nov 12, 2026